Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Ritter

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2023
Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 TrialBrett A Morris, Emma E Holmes, Nicholas J Anger, et al.
Practical Radiation Oncology|February 9, 2025
Neoadjuvant SBRT plus Elective Nodal Irradiation with Concurrent Capecitabine for Patients with Resectable Pancreatic Cancer: Survival Analysis of a Prospective Phase 1 TrialMustafa M Basree, Jacob S Witt, Nataliya V Uboha, et al.
International Journal of Radiation Oncology, Biology, Physics|September 17, 2020
A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic CancerJacob S Witt, Aleksandra Kuczmarska-Haas, Meghan Lubner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2016
Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancerSkyler Bryce Johnson, Pamela R Soulos, Timothy D Shafman, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2023
Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 TrialBrett A Morris, Emma E Holmes, Nicholas J Anger, et al.
Practical Radiation Oncology|February 9, 2025
Neoadjuvant SBRT plus Elective Nodal Irradiation with Concurrent Capecitabine for Patients with Resectable Pancreatic Cancer: Survival Analysis of a Prospective Phase 1 TrialMustafa M Basree, Jacob S Witt, Nataliya V Uboha, et al.
International Journal of Radiation Oncology, Biology, Physics|September 17, 2020
A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic CancerJacob S Witt, Aleksandra Kuczmarska-Haas, Meghan Lubner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2016
Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancerSkyler Bryce Johnson, Pamela R Soulos, Timothy D Shafman, et al.
Pageof 4